Navigation Links
Biosimilars Market worth $1,954 Million by 2018
Date:11/18/2013

DALLAS, November 18, 2013 /PRNewswire/ --

The "Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018", provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global Biosimilars Market along with the estimates and forecasts of the revenue and share analysis.

Browse 80 market data tables and 80 figures spread through 320 pages and in-depth TOC on "Biosimilars Market".

http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

Early buyers will receive 10% customization on this report.

The global Biosimilars Market is segmented on the basis of products, applications, and services. By product, the global Biosimilars Market is further segmented into recombinant non-glycosylated proteins (insulin, granulocyte colony-stimulating factor (G-CSF), interferon, and human growth hormone), recombinant glycosylated proteins (erythropoietin, monoclonal antibodies, and follitropin), and recombinant peptides (glucagon and calcitonin). The recombinant glycosylated proteins segment is the largest segment and accounts for a share of 40% of the global Biosimilars Market in 2013 at an estimated $314.2 million and is expected to grow at a CAGR of 17.5% from 2013 to 2018. The biggest factor behind the growth of this segment is the increasing demand for second-wave Biosimilar products, such as insulin and interferon, for the treatment of diabetes and infectious disorders.  Of all segments under the product category, the monoclonal antibodies segment is the fastest-growing segment at an estimated CAGR of more than 40% from 20
'/>"/>

SOURCE MarketsandMarkets
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
2. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
3. Biosimilars: Global Markets
4. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
5. FDA New Guidelines for Biosimilars and Biobetters: An Outlook for 2013
6. Biosimilars Market Expected to Soar
7. Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
8. XBiotech Expands Portfolio to Include Biosimilars
9. Recall of Anemia Drug Omontys Rings Alarm Over Biosimilars
10. Seminar Spotlights Key Trends in Biologics and Biosimilars
11. Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... South Korea , March 4, 2015 ... biopesticide company, in August of last year. As part ... Kyung Bon Koo continuing his role as ... , President of Vegalab S.A., will work alongside Koo ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 ...
(Date:3/4/2015)... March 4, 2015 ... Paris en décembre 2011, l,étude ...   », qui compare   l es ...   sorafénib dans le carcinome hépatocellulaire avancé, a ... du foie avancé   ; les résultats sont ...
(Date:3/3/2015)... DIEGO , March 3, 2015  Halozyme Therapeutics, Inc. ... Barclays 2015 Global Healthcare Conference in Miami, FL ... a.m. PT. David A. Ramsay , Chief Financial Officer, ... be webcast through the "Investors" section of Halozyme,s corporate website ... available for 90 days following the event. To access the ...
(Date:3/3/2015)... ON , March 3, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... $3.7 million.  The orders are for odour control projects in ... and Asia . "Bidding activity ... , President and CEO. "After a high volume year for bidding ... into the New Year.  The recent orders reflect the organization,s renewed ...
Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2
... , Trial conducted pursuant to Special Protocol ... CITY, Dec. 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... biopharmaceutical company focused on oncology and endocrine therapy, today ... ("Keryx") ( KERX), of a Phase 3 registration clinical ...
... , , SAN MARINO, Calif., Dec. 15 Epeius ... genetic medicine, gained international validation of the cutting-edge science behind ... the world rediscovered the Cyclin G1 gene to ... and thus a prime target for anti-cancer therapies. Recently, scientists ...
... , , , SAN DIEGO, Dec. 15 Aethlon Medical, Inc. ... and Dr. Wayne Comper have joined the Science Advisory ... Comper are leading researchers in the exosome field. ESI, a wholly ... discovery that the Hemopurifier®, a medical device being advanced as an ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... The levels of contamination to water and sediment in Frenchman,s ... in some cases by as much as 250 per cent, ... of Toronto Scarborough. This is largely due to large amounts ... the study finds. Roads, parking lots and railways are ...
... Microbiology (ASM) William A. Hinton Research Training Award will ... of Biological Sciences, The University of Texas at El ... underrepresented minorities in microbiology. This award honors William A. ... African-Americans to join the ASM. Aguilera received his ...
... The ongoing El Nio of 2010 is affecting ... the West Coast fishing industry, according to scientists at ... Researchers with the California Cooperative Oceanic Fisheries Investigations ... report a stronger than normal northward movement of warm ...
Cached Biology News:Road salt and cars produce extreme water contamination in Frenchman's Bay, UTSC research reveals 2Road salt and cars produce extreme water contamination in Frenchman's Bay, UTSC research reveals 3Improved near-real-time tracking of 2010 El Niño reveals marine life reductions 2Improved near-real-time tracking of 2010 El Niño reveals marine life reductions 3
... The BioGenex VISION Sytem is ... that comes with proprietary digital imaging ... for digital image acquisition, analysis, archving/retrieval ... is a state-of-the-art digital imaging system ...
... -mr agarose is specifically for ... endoosmosis, and is recommended for ... weight proteins or complexes that ... of molecular sieving in polyacrylamide ...
... is used for second-dimension SDS-PAGE sample ... place in PROTEAN Plus cells. Bromophenol ... allow monitoring of electrophoresis runs. The ... in 1x Tris, glycine, SDS, and ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Biology Products: